Scientific Panel on Plant Protection Products and their Residues

Minutes of the meeting of the Working Group on developmental neurotoxicity (DNT) of acetamiprid and imidacloprid

Held on 2 December 2014 in Parma (Italy)

(Agreed on 14 January 2015)

Participants

• Working Group Members:
  o Antonio F. Hernández-Jerez (Chair)
  o Karen Ildico Hirsch-Ernst (via teleconference)
  o Alberto Mantovani
  o Colin D. Ockleford

• Hearing Experts:
  o None

• European Commission and/or Member States representatives:
  o None

• EFSA:
  o PRAS Unit: Federica Crivellente, Manuela Tiramani
  o AMU Unit: Didier Verloo

1. Welcome and apologies for absence
The Chair welcomed the participants.
Apologies were received from Anna Price and Laura Ricceri

2. Adoption of agenda
The agenda was adopted without changes.
3. Declarations of interest

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes\(^1\) and the Decision of the Executive Director implementing this Policy regarding Declarations of Interests\(^2\), EFSA screened the Annual Declaration of interest and the Specific Declaration of interest) filled in by the expert invited for the present meeting. No conflicts of interests related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of interest at the beginning of this meeting.

4. Discussion of the Bayer and Exponent reports

The documentation provided by the companies regarding the Opinion prepared by the PPR Panel was analysed and discussed. In particular, it was discussed whether the information provided would trigger a re-assessment of the DNT potential of acetamiprid and imidacloprid and a consequent change of the current Opinion.

The WG agreed that the submitted information did not trigger a change of the current Opinion for both a.s. (see attachments). The view of the WG will be discussed in the 71\(^{st}\) Plenary of the PPR Panel.

---


Annex I

Interests and actions resulting from the screening of Specific Declaration of Interests (SDoI)\(^3\)

a) With regard to this meeting Dr. Karen Ildico Hirsch-Ernst declared the following interest: BfR has been involved in the assessment of imidacloprid within the context of Germany serving as RMS. In accordance with EFSA’s Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director implementing this Policy regarding Declarations of Interests, and taking into account the specific matters discussed at the meeting in question, the interest above was not deemed to represent a conflict of Interest for the expert concerned.

---

\(^3\) The Annual Declarations of Interests have been screened and approved before inviting the experts to the meeting, in accordance with the Decision of the Executive Director implementing the Policy on Independence regarding Declarations of Interests.
Response of PPR Panel to the Nippon Soda Co., Ltd. Report on the potential DNT of acetamiprid

The Nippon Soda Co., Ltd. report presentation focuses on both new data claimed not having been taken into account by the PPR Panel and on data not taken in due account by the PPR Panel. Nippon Soda Co., Ltd. deemed the PPR conclusions to be based on incorrect facts or outdated assumptions about variability and ontogenic pattern of control data (Slides 2-5)\textsuperscript{1}.

Response. In its Scientific Opinion on DNT (2013), the PPR Panel identified technical shortcomings and pitfalls in the \textit{in vivo} DNT test of acetamiprid for regulatory purposes. In particular important variability and uncertainties in determinations of auditory startle response, motor activity and learning and memory findings were noted. In spite of the efforts made by Nippon Soda Co., Ltd. in reanalysing data with new statistic tools and comparing with historic control and interquartile range, uncertainties still remain. In consequence, a potential developmental neurotoxicity of acetamiprid still cannot be reliably ruled out.

The Nippon Soda Co., Ltd. report indicates that the PPR Panel had no access to the following key documents (Slide 12): a) ACE DNT Study Report \textsuperscript{[2003, revised 2008]}, b) \textit{[2006]} (positive and historical control data, detailed explanation of methods, statistical analysis for males and females separately at each age); c) Nippon Soda Co., Ltd. statistical analyses \textit{[2007a]} (males and females combined at each age in response to EPA request for global statistical analysis).

Response. The PPR Panel has reviewed these documents and noted that they do not challenge the conclusion reported in the DNT opinion recommending conservatively decrease of the NOAEL of acetamiprid from 10 to 2.5 mg/kg bw/day. More detailed considerations on specific issues are reported below.

\textsuperscript{1} Nippon Soda Co., Ltd. submitted a Presentation to EFSA on behalf of Nippon Soda, June 4, 2014. The relevant slides of the presentation are mentioned in the text.
Variability of data and guideline compliance

New information proves acetamiprid DNT study is not more variable than other DNT studies (Slide 9).

Response. The open scientific literature (Raffaele et al., 2010) has acknowledged the need for improvements in data evaluation and interpretation of DNT studies that often exhibit data variability. This study noted that improvements in study conduct and data evaluation would decrease the uncertainty involved in utilizing some of these data, particularly by addressing concerns about possible lack of sensitivity for some test methods.

As aforementioned, the draft document “Retrospective performance assessment of the test guideline 426 on DNT” (2005) cited the criticism that variability of some endpoints (e.g., motor activity, morphometrics) was too great to be useful. The International STakeholder NETwork (ISTNET) meeting held in Zurich in January 2014 recognized the limited confidence in the use of results of animal-based test methods currently used for developmental neurotoxicity evaluation for regulatory purposes (Crofton et al., 2014).2 Although these criticisms do not invalidate the in vivo DNT studies, they should be taken into account for a proper interpretation of results, particularly when there is large variation in the results.

Startle values at 10 mg/kg bw/day are within the interquartile range of historical control data (so entirely typical of controls) (Slide 11).

Response. The EFSA opinion on statistical significance and biological significance (2011) notes that the assumptions derived from a statistic analysis should be related to the study design. Analyses should not be carried out independently of such information in order to avoid biased or unreliable results. The comparison of particular effects with the historical control data is a kind of post hoc criterion whose validity is missing. According to the above statement, only measurements below the percentile 25 or above the percentile 75 (lower and upper limits of the interquartile range, respectively) of historical control data would be considered as positive findings. Taking into account the variability of data, this procedure could lead to many false negative results due to lack of sensitivity. As a general statement, the PPR considers that the historical values may be of use when the relationship of a given effect with treatment is doubtful; conversely, historical values should not be used to discount findings that are dose-related, statistically significant and biologically relevant.

---

2 Crofton K, Fritsche E, Ylikomi T, Bal-Price A. International Stakeholder NETwork (ISTNET) for creating a developmental neurotoxicity testing (DNT) roadmap for regulatory purposes. ALTEX 2014; 31: 223-224
Study was well-conducted and complies with guidelines (Slide 22).

Response. The study of Raffaele et al (2010), which is mentioned in slides 16-18, states “For learning and memory assessments, both the EPA and the OECD guidelines provide considerable flexibility in methodology. Given the varying sensitivity of different types of learning and memory procedures for detecting deficits and the likelihood that the specific deficits produced will vary across chemicals it is possible that the procedures currently in use may allow some learning and memory deficits to remain undetected”. This implies there will be occurrence of false negative results. Accordingly, the PPR Panel repeats its remarks that no conclusion can be made on the effects of acetamiprid on learning and memory because of the highly variable data.

Startle response

The Nippon Soda Co., Ltd. reports claim that there is an apparent dose-related decrease in maximum startle amplitude. The question is whether the decrease observed at 10 mg/kg/day is an adverse effect. The report also states that more rigorous quantitative evaluation of these data using RANOVA indicates a statistically significant overall dose effect at 45 mg/kg bw/day but not at 10 mg/kg bw/day. According to Nippon Soda Co., Ltd., the apparent decreases of 27 and 40% at PND 20 and PND 60, respectively, at 10 mg/kg bw/day are comparable to coefficient of variations published by experts in the field. Re-analyses of data using new statistical analyses (RANOVA, repeated measures analysis of variance) supported a NOAEL of 10 mg/kg/day.

Response. Nippon Soda Co., Ltd. does not consider the decrease in startle response at 10 mg/kg bw/day as treatment-related. However, the PPR Panel does not support these new data as they represent a post hoc analysis. The statistical analysis was apparently shifted to support the null hypothesis (no difference between intermediate dose and controls), which is not appropriate. The same objections apply to the data evaluation record on acetamiprid prepared for US-EPA, which showed a completely opposite result as male rats treated with mid and high doses (10 and 45 mg/kg bw/day, respectively) exhibited statistically significantly differences from the control group. The Panel stands by its previous recommendation of lowering the NOAEL from 10 to 2.5 mg/kg bw/day because the magnitude of the decrease of maximum auditory startle response is biologically relevant and treatment-related and uncertainties still remain from the assessment of motor activity, and learning and memory evaluation. Since the terms of reference of the Opinion required a reconsideration of existing health reference values, the PPR Panel has identified a NOAEL of 2.5 mg/kg bw/day using the available data and taking into due account the possibility that uncertainties and variability in the available data may mask a false negative result. Hence, the Panel recommends a conservatively lower NOAEL to counter any potential neurodevelopmental risk for consumers.

Nippon Soda Co., Ltd. also states that new BMD (Benchmark Dose) analyses further support a NOAEL of 10 mg/kg bw/day (Slides 51-52). The selection of BMR (Benchmark Response) seems to be tailored to satisfy Nippon Soda Co., Ltd. claims, e.g. that male BMDL (12.6 and 13.1 for PND 20 and 60, respectively) falls close to NOAEL of 10 mg/kg /day. In some instances, particularly in the absence of consensus on the level that is considered to be adverse, the US-EPA has used a BMR as a change in the parameter observed equal to one standard deviation of the mean of the control group\(^4\). The use of BMR based on data showing high coefficient of variations from historical control data (“21 oral control studies”) was not deemed appropriate by the PPR Panel because of the following reasons: a) it would lead to a high BMD that may underestimate health risks; b) Nippon Soda Co., Ltd. is not sufficiently transparent as the BMDL (BMD lower 95% confidence limit) is not provided (see table 6 of the “Nippon Soda Co., Ltd. response to EFSA PPR Scientific Opinion on the acetamiprid DNT study”, 10 March 2014); c) recently, EFSA acknowledged that the hazard characterization of pesticides should make progress in implementing this methodology but it was not used for the peer review of chlorpyrifos\(^5\). In a similar way, the PPR Panel declined to conduct an assessment based on BMD as these data were not submitted for the EU peer review.

Nippon Soda Co., Ltd. finally concludes that the startle response of male rats at 10 mg/kg dose level is close to the mean of historical controls (Slide 59). However, as has already been mentioned, the PPR Panel notes that comparison with historical controls may lead to false negative results and thus consumers’ health would not be properly protected.

**Motor activity**

Motor activity is claimed to be highly variable based on recent retrospective analysis of submitted DNT studies. Nippon Soda Co., Ltd. compared results with the interquartile range of historical control data to determine if the change in motor activity is adverse (Slides 68 and 70).

*Response*. The PPR Panel noted that if problems with concurrent controls were observed, any positive finding (of adverse effect) in treated animals could be masked. The Panel reiterates the general remark already presented, that the historical values may be of use when the relationship of a given effect with treatment is doubtful; conversely, historical values should not be used to discount findings that are dose-related, statistically significant and biologically relevant. Nippon Soda Co., Ltd. also states that ontogenic response is not always consistently demonstrated in controls and that treated groups demonstrate “normal” ontogenic response (slide 72). Again, it can be seen that the flexibility of *in vivo* DNT testing may lead to false negative results, also because of the unclear and fluctuating definition of the boundaries of “normality”. In this specific case, the explanation given in slide 80 (“the normal developmental pattern, i.e. inverted U-shaped

\(^4\) [http://www.epa.gov/iris/toxreviews/1010tr.pdf](http://www.epa.gov/iris/toxreviews/1010tr.pdf)

pattern, is not as consistent as originally thought”) is not satisfactory because the lack of consistency may mask adverse effects in treated animals.

**Learning and memory**

Nippon Soda Co., Ltd. concludes that the variability and quality of learning and memory procedures is comparable to, if not better, than other DNT studies (Slide 84).

*Response.* As aforementioned, the considerable flexibility in methodology for learning and memory assessments and the varying sensitivity of different procedures currently in use may allow some learning and memory deficits to remain undetected (Raffaele et al., 2010). Also, the 2014 ISTNET meeting recognized the limited confidence in results of animal-based test methods currently used for developmental neurotoxicity evaluation for regulatory purposes (Crofton et al., 2014). More in general, the boundaries of physiological “normality” (as different from purely statistical values) are not clearly identified for many DNT relevant parameters. In addition, as summarised in a recent review (Driscoll et al. 2014)⁶ cognition encompasses different aspects of cognitive functioning that are subserved by distinct neural systems. Animal DNT studies typically consist of a single learning and memory task that is expected to detect all potential effects on cognitive functioning; however, executive functioning is poorly assessed in most DNT studies. The use of tasks for assessing executive functioning (attention, working memory, inhibitory control, and planning) would provide both a wider range and greater sensitivity of the test battery and a more complete characterization of effects. Therefore, the PPR Panel agrees with the Data Evaluation Record prepared for US-EPA in the sense that learning and memory and motor activity were inadequately assessed. The high variability in some data was deemed as a deficiency of the DNT study and therefore no conclusion may be drawn.

**Conclusion**

Nippon Soda Co., Ltd. concludes that, based on robust statistical analysis and comparison with the interquartile range of the historical control data, there are no effects at 10 mg/kg bw/day (Slide 101). However, the PPR Panel considered 2.5 mg/kg bw/day as the NOAEL for startle (Slide 23).

*Response.* The PPR Panel did not make this claim; instead, the Panel noted that the data available do not allow any firm conclusion to be drawn since important endpoints such as motor activity, learning and memory evaluation could not be properly assessed and that insufficient arguments support the straight conclusion that reduced auditory startle responses in offspring first noted at 10 mg/kg bw/day was not related to treatment. In consequence, the PPR Panel recommended the

---

lower NOAEL (2.5 mg/kg bw/day) until such time as new and scientifically sound evidence is provided.

The PPR Panel does not consider appropriate to conduct post hoc analysis of data using different statistical approaches as it might lead to results supporting (or not supporting) a certain view. The most appropriate statistical methods to be used for the study results should be defined while designing the study, not after getting the data.

**Overall conclusion**

With the data available and the new and limited data presented by the BCS and Nippon Soda Co., Ltd., there is insufficient evidence to discard the indications of potential developmental neurotoxicity provided by the regulatory DNT studies performed on imidacloprid and acetamiprid. Accordingly, the recommendation of modifying health-bases reference levels made by the PPR Panel in its DNT Scientific Opinion (2013) continues to be supported by the panel. The PPR Panel notes that until more consistent evidence is provided, uncertainties still persist and hence, human health cannot be guaranteed with the current (unrevised) levels.

The PPR Panel has taken a precautionary approach in its scientific opinion by also considering recent evidence on potential delayed neurological disturbances following prenatal exposure to neurotoxicants. This type of exposure, which may adversely impair the nervous system, has been suggested to be associated with a number of developmental disabilities, such as learning disabilities, attention-deficit hyperactivity disorder, dyslexia, sensory deficits, mental retardation and autism spectrum disorders.\(^7\)

The current in vivo DNT studies may not be sensitive enough to detect subtle effects, such as those on cognition, behaviour or brain morphometry, and might lead to false negatives. Therefore, the scientific assessment of in vivo DNT studies should be conservative in their application.

---

\(^7\) Giordano G, Costa LG. Developmental Neurotoxicity_Some old and new issues. ISRN Toxicology. Volume 2012, Article ID 814795, 12 pages
Response of PPR Panel to Bayer Crop Science (BCS) report from June 2014 on the potential DNT of imidacloprid

The major point of disagreement between BCS and the PPR Panel is the interpretation of morphometric data. BCS contends that imidacloprid caused no morphometric effects in their developmental neurotoxicity (DNT) study; meanwhile BCS recognizes that their morphometric investigations were limited to the high dose and control groups. By contrast, the PPR Panel considered the morphometric data a source of concern and the lack of intermediate and low dose data as important missing information. Using the available data it is impossible to assess a dose-response relationship for morphometric changes. The level of uncertainty identified in brain morphometry precludes a robust characterization of the DNT potential of imidacloprid.

The BCS report (page 5) states that differences in brain morphometry at the highest dose level were spurious and unrelated to treatment. The PPR Panel disagrees with this interpretation and requested more data (particularly regarding the intermediate dose level). However, this relevant information was not provided and hence the concerns raised by the Panel as to a potential DNT effect of imidacloprid cannot be ruled out.

BCS states that complex biological multi-parameter experiments such as the DNT study show a number of differences between treated groups and controls that could either be spurious or caused by the test substance. The statement could overinterpret true differences as potential false positive results due to variation in the test system might be further used to exclude any potential finding from in vivo DNT studies, making them unfit for regulatory purposes. By finally bringing this unwarranted flexibility to the interpretation of DNT studies, many statistically significant findings observed were challenged without foundation. On this basis, the claim could be advanced that it would not make sense to perform such studies. EFSA has recommended the correct use and understanding of the concepts of biological relevance and statistical significance when conducting risk assessments as both terms are often confused. A particular outcome could be statistically significant, but without any biological relevance, and vice versa. The concept of biological relevance refers to an effect of interest or to the size of an effect that is considered
important and biologically meaningful and which, in risk assessment, may have consequences for human health. In addition, the biological relevance of any change found should be of primary importance in the assessment rather than the specific level of statistical significance.\textsuperscript{1}

The PPR Panel notes that great variation in data collected from DNT studies is a limitation to identification of dose-related and statistically significant associations. Variation of this extent can erroneously lead to firm negative conclusions concerning DNT, as some treatment-related effects in these studies could be masked and go unrecognised. The same applies when data are compared to historical controls, as the range of historical variation may be larger than the magnitude of effects observed in treated animals.

**Brain morphometry**

The BCS report provides the following table of brain morphometric measurements:

<table>
<thead>
<tr>
<th>Brain Structure</th>
<th>PND 11</th>
<th></th>
<th>PND 75</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male %</td>
<td>Female %</td>
<td>Male %</td>
<td>Female %</td>
</tr>
<tr>
<td>Frontal Cortex</td>
<td>-3.4</td>
<td>-4.1</td>
<td>+1.2</td>
<td>-1.7</td>
</tr>
<tr>
<td>Parietal Cortex</td>
<td>+0.5</td>
<td>-0.8</td>
<td>+1.8</td>
<td>-1.7</td>
</tr>
<tr>
<td>Hippocampal gyrus</td>
<td>+0.2</td>
<td>-4.1</td>
<td>-8.1</td>
<td>-1.1</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>+5.5</td>
<td>+1.3</td>
<td>-3.2</td>
<td>-0.3</td>
</tr>
<tr>
<td>Caudate-Putamen</td>
<td>+0.3</td>
<td>-5.5</td>
<td>+1.0</td>
<td>-1.9</td>
</tr>
<tr>
<td>Corpus Callosum</td>
<td>-0.6</td>
<td>-27.6</td>
<td>+6.0</td>
<td>-7.1</td>
</tr>
</tbody>
</table>

Percent change in different rat brain structures stratified by sex between the highest dose tested and concurrent controls a two different time periods.

The table shows a consistent pattern of decreased morphometric measurements in females at both ages for all measurements with the exception of cerebellum at PND11 (cerebellum is a structurally unusual and primitive part of the CNS situated at the junction of the brain and brain stem concerned with co-ordination of movement. Although only 10% of the skull contents by weight, this part contains approximately 50% of the neurons). The PPR Panel was concerned about this pattern and although it does not directly demonstrate neurotoxicity, it cannot be dismissed, especially considering the magnitude of decrease in corpus callosum dimension. The fact that a similar trend in brain morphometry was not observed in male rats does not necessarily

\textsuperscript{1} Scientific Opinion. Statistical Significance and Biological Relevance. EFSA Journal 2011;9(9):2372
means that the effect is irrelevant as it is well known that some adverse effects are gender-dependent (vide infra). The data evaluation record (DER) prepared for US-EPA\(^2\) also considered changes in one sex as toxicologically plausible, thus gender-dependency should not be the basis for rejecting their relevance. In addition, epidemiological studies on birth cohorts evaluating neurodevelopmental effects have found adverse effects in only one sex\(^3,4\).

The 5.5% decrease in caudate-putamen at PND 11 was borderline statistically significant (p=0.07), among other reasons because the sample size was not large enough to detect the effect. This finding persisted at PND 75 (study termination, corresponding stage to adult human) where a statistically significant 1.9% decrease was observed compared to concurrent controls. At PND11 the main change was the markedly and significantly reduced thickness of corpus callosum (27.6%) in female pups; this reduction persisted until study termination (7.1%) albeit without reaching statistical significance, and it was considered by the PPR Panel as a biologically relevant finding because of its magnitude. These findings did not correspond to changes in mean brain weights, suggesting a possible effect on the development of specific brain components. This consistency over time was also considered by the evaluation record prepared for US-EPA as treatment-related; accordingly, the record recommended that the registrant should examine intermediate doses using brain morphometry. The PPR is in agreement with the DER in regretting the lack of morphometric data at the lower dose levels. Its absence precludes any proper dose-response assessment.

Crofton et al (2011)\(^5\) assessed variability of morphometric assessments of in vivo DNT studies and concluded that "variability in the most common morphometric measures is modest, less than that associated with body weights, and not significantly greater at PND 11 than in young adults". However, these authors assessed morphometric data for cortex, cerebellum and hippocampus (but not for putamen-caudate and corpus callosum). Cortical width is thinner than caudate-putamen width as can be seen in the original DNT study on imidacloprid performed by BCS. Owing to gaps in the available data, the PPR Panel could only propose health reference values (as requested by the terms of reference) taking into account the uncertainties identified as regards brain morphometry, and considered that more data are needed. Accordingly, as new and more data are made available any dose-response relationship present can be evaluated and the PPR recommendation of modifying the current health-based reference values can be reconsidered.

\(^2\) [http://www.epa.gov/opp00001/chem_search/cleared_reviews/csr_PC-129099_undated_a.pdf]

\(^3\) Horton MK, Kahn LG, Perera F, Barr DB, Rauh V. Does the home environment and the sex of the child modify the adverse effects of prenatal exposure to chlorpyrifos on child working memory? Neurotoxicol Teratol 2012; 34: 534–541


BCS suggests that these findings are spurious and invoked some of the differences at study termination as a result of the unusually high mean value for the controls in this study. The values were close to the upper-limit for the 19 DNT studies that constitute their historical control. However, if the variation within historical controls is invoked as a rationale for discounting the statistical or biological relevance of findings, in vivo DNT studies would not be useful for regulatory purposes. This follows because the magnitude of changes observed in a given test should be high enough to exceed the full range of historical control variability in order to be considered as a positive finding. A substantial level of uncertainty would remain and potential harm to consumers’ health could not be properly guarded against. The PPR considers that the historical values may be of use when the relationship of a given effect with treatment is doubtful; conversely, historical values should not be used to discount findings that are dose-related, statistically significant and biologically relevant. In the specific case of imidacloprid, it would have been useful to have morphometric data from intermediate doses as previously requested. The aforementioned data evaluation record prepared for US-EPA also identified this data gap as a study deficiency and asked the registrant to submit more data, at least for an intermediate dose.

The PPR Panel considered the relevance of morphometric analyses as endpoint for hazard characterization. Tsuji and Crofton (2012)\(^6\) have reported that morphometric analyses of brain regions, properly performed, can supply valuable data for regulatory authorities. In a review of DNT studies (Raffaele et al., 2010)\(^7\) it was reported that the Office on Pesticide Programs (OPP) in US-EPA identified major issues in some of the submitted DNT studies that complicated both the interpretation of study results and the possible use of the studies as a point of departure for risk assessment. One of these issues was failure to evaluate brain morphometric measurements at low and mid doses, when significant differences in morphometry were seen between high dose and control animals. The same paper (Raffaele et al., 2010) indicates that in contrast to the lack of qualitative neuropathological findings, changes in quantitative neuropathological findings (i.e. linear morphometric measurements) were seen in a substantial number of studies. Hence, it is possible that a more detailed and extensive quantitative neuropathological examination might identify more treatment-related changes or changes at lower dose levels. This possibility is supported by the frequent detection of effects on brain weight and quantitative (linear morphometric) neuropathology, where effects at LOAEL were detected in 14/69 and 22/69 studies submitted to OPP, respectively.

Recent data indicate the relevance for humans of brain morphometry changes. Raugh et al (2012)\(^8\) have reported significant associations of prenatal exposure to standard use levels of

---

\(^6\) Tsuji R, Crofton KM. Developmental neurotoxicity guideline study: issues with methodology, evaluation and regulation. Congenit Anom (Kyoto) 2012; 52: 122-128


chlorpyrifos with structural changes in the developing human brain. In particular, upper tertile levels of this organophosphate in cord blood had a measureable effect on brain structure in a sample of 40 children 6–11 years of age, who showed frontal and parietal cortical thinning. Thus, an inverse dose–response relationship between chlorpyrifos exposure and cortical thickness was concluded, further supporting the need for a careful consideration of brain morphometry in DNT studies.

Motor activity

The BCS report reviews the main results obtained in the DNT study on imidacloprid performed in 1999 (page 6) but fails to mention the magnitude of the decrease in motor activity, which ranged from 31 to 38% (in females and males, respectively) at PND 17 in high-dose animals and then a 37% decrease in females at PND 21. Although differences were not statistically significant, the effects on motor activity were deemed to be treatment related and taken into account because of its biological relevance. The apparent reversibility does not necessarily mean that the effect is not adverse, as the decrement in motor activity in pre-weaning rats might have an impact in later life on different domains.

The apparent reversibility of a functional impairment and the persistence of a morphological change are not necessarily contradictory findings. Regardless of any functional compensation or adaptive response of the developing brain, these adverse effects were considered of concern by the PPR Panel as indicators of potential developmental neurotoxicity. Similarly, in spite of the fact that reversible inhibition of brain acetylcholinesterase induced by N-methylcarbamates can be recovered over time, this finding is considered as an adverse one. For regulatory purposes, transient effects are also relevant and cannot be dismissed because otherwise a full protection of human health would not be afforded.

The BCS report states that the decreased motor activity occurred in association with the period of higher exposure to pups, and no residual effect on PND 60 was observed, leading to the conclusion that this finding is consistent with results of acute neurotoxicity studies also performed in the same laboratory. However, based on the above considerations, the PPR Panel notes that, in spite of being a transient finding, its toxicological relevance has to be taken into account. In addition, there is increasing evidence that exposures occurring during the prenatal or early postnatal periods may lead to delayed adverse effects later in life. In this regard, it has been suggested that subclinical chemical injury may kill silently a fraction of the cells required to sustain brain function in later life. While these latent impairments cause no symptoms in childhood, they may be unmasked during the neuronal attrition associated with aging because of an age-related decline in functional reserve capacity of the brain. In particular, there is uncertainty whether the reduced motor activity clearly observed in pups and apparently reversed at study termination (young adulthood) might signal toxicity mechanisms with an impact on later

---

life, e.g., on the aging brain. Accordingly, the precautionary principle has to be applied to this case until there is sufficient evidence to the contrary.

The BCS report states that “a transient decrease in activity is a non-specific effect that can result from such diverse causes as hypoglycaemia, hypothermia, gastric disturbance or toxicity to various systems, including the central nervous system. Due to this lack of specificity it is rarely appropriate to associate a transient decrease in motor activity with a particular mode of action”. However, in the 2013 Scientific Opinion on cumulative assessment groups (CAGs)\(^\text{10}\), the PPR Panel considered “decreased motor activity” as a relevant and specific effect and BCS did not challenge this during the public consultation of the opinion. On the other hand, BCS acknowledges that the reduced motor activity reflects “acute toxicity rather than DNT”. In doing so, BCS is explicitly considering this effect as an adverse outcome: all the possible alternative causes invoked by BCS (e.g., hypoglycaemia, hypothermia) are, indeed, substance-induced adverse effects.

BCS summarizes the position of the PPR Panel by stating in page 5 of the BCS report “Differences in brain measurements in rats at the highest dietary level were associated with exposure to imidacloprid during development and evidence of impaired motor control (decreased motor activity); this indicates a possible DNT potential of imidacloprid”. However, the Scientific Opinion did not draw this conclusion, rather it observed consistency between those two findings: morphometric and functional. The PPR Panel, in its 2013 DNT scientific opinion\(^\text{11}\) offered a plausible explanation for the link between caudate-putamen width and motor activity: “Since putamen is involved in movement regulation and influences various types of learning, a decrease in thickness of this structure could be due to decreased number of neurons/glia ultimately leading to decreased motor activity”. The lack of morphometric data for at least intermediate doses, together with the reduced motor activity observed in pups at the highest dose, prevented the Panel from ruling out any potential adverse effect on the developing brain in the lower dose ranges.

The draft document “Retrospective performance assessment of the test guideline 426 on DNT” (2005)\(^\text{12}\) cited the criticism that variability of some endpoints (e.g., motor activity, morphometrics) was too great to be useful. More recently (January 2014), the International STakeholder NETwork (ISTNET) held a meeting in Zurich to build consensus on development and use of in vitro methods to deliver useful data for regulatory decisions. There was consensus that animal-based test methods currently used for developmental neurotoxicity evaluation for regulatory purposes were not being routinely used owing to high costs, use of large numbers of animals and limited confidence in the use of results for regulatory purposes (Crofton et al., 2014)\(^\text{13}\). These controversial opinions do not invalidate the in vivo DNT study for hazard identification

\(^{12}\) http://www.oecd.org/dataoecd/57/7/39824463.doc
\(^{13}\) Crofton K, Fritsche E, Ylikomi T, Bal-Price A. International Stakeholder NETwork (ISTNET) for creating a developmental neurotoxicity testing (DNT) roadmap for regulatory purposes. ALTEX 2014; 31: 223-224
and risk assessment, but rather they calls for the need of incorporating improvements in this important protocol.

The PPR Panel interpreted motor activity and morphometry findings into a broader context by taking into account other studies (Abou-Donia et al, 2008 and Kimura-Kuroda et al., 2012). Whilst these were not considered useful for regulation, they do inform about the mechanisms and the potential for damage to the CNS. In the study of Abou-Donia et al (2008)\textsuperscript{14} a single large non-lethal dose of imidacloprid administered on gestational day 9 produced significant deficits in sensorimotor performance (inclined plane, beam-walking and forepaw grip) and an increased expression of GFAP (glial fibrillary acidic protein) in motor cortex and the dentate gyrus of the hippocampus of the offspring on PND 30. Authors concluded that these changes may have long-term adverse health effects in the offspring as neurobehavioral deficits may reflect dysfunction at multiple anatomical areas in the nervous system, and accumulation of GFAP is a characteristic response of both the immature and adult brain to a variety of neurotoxic insults.

Kimura-Kuroda et al (2012)\textsuperscript{15} carried out an in vitro study and suggested that excitation and/or desensitisation of nicotinic acetylcholine receptors (nAChRs) by imidacloprid might affect the developing mammalian nervous system as it exerts excitatory effects on nAChRs of cerebellar granular cells at low concentrations (1 µM and above). The PPR Panel estimated a NOAEL for DNT of imidacloprid of 5.5 mg/kg bw/day. This figure corresponds to approximately a $T_{\text{max}}$ of 15 µM (as reported in the PPR Panel scientific opinion) and the Panel notes that such a $T_{\text{max}}$ falls within the dose range assayed by Kimura-Kuroda et al. (2012) that induced adverse effects on cerebellar granular cells (1-100 µM). That figure is also in the range of concentrations reported to change the membrane properties and function of neurons having nAChRs in cholinergic synapses of the stellate cells of the mouse cochlear nucleus ($\geq 10$ µM for $< 1$ min)\textsuperscript{16}. From these results, it can be inferred that a clearly effective in vitro concentration corresponds to a dose level in vivo devoid of any neurotoxic effects in the available DNT studies as stated in the scientific opinion (2013); however, there would only be cause for concern if the $T_{\text{max}}$ is achieved at neuronal level.

\textsuperscript{14} Abou-Donia MB, Goldstein LB, Bullman S, Tu T, Khan WA, Dechkovskaia AM, Abdel-Rahman AA. Imidacloprid induces neurobehavioral deficits and increases expression of glial fibrillary acidic protein in the motor cortex and hippocampus in offspring rats following in utero exposure. J Toxicol Environ Health A 2008; 71: 119-130


More recently, Keil et al (2014) have reported a weak positive association between autism spectrum disorder and maternally-reported use of imidacloprid during pregnancy in the CHARGE (CHildhood Autism Risks from Genetics and Environment) case–control study.

Considering the available evidence, the PPR Panel concluded that imidacloprid may have potential DNT effects. Therefore, taking a precautionary approach, health-based reference values should be revised accordingly to conservatively protect human health as indicated in the DNT Scientific Opinion (2013).

**Gender dependent effects in DNT studies**

In the BCS report attention is drawn to gender specific effects and the suggestion is made that these are probably spurious on the grounds that toxic effects are an unlikely occurrence. This criticism of the EFSA opinion is misguided and ill informed as numerous studies have shown such effects. They include:

1. Special issue of "Toxicology" on Gender development in Neurotoxicity. Volume 311, Issues 1–2, Pages 1-86 (6 September 2013)
2. Beronius A, Johansson N, Rudén C, Hanberg A. The influence of study design and sex-differences on results from developmental neurotoxicity studies of bisphenol A: implications for toxicity testing. Toxicology 2013; 311: 13-26. [This study suggests that DNT studies conducted according to the standardized OECD TG 426 may overlook sensitive effects of bisphenol A, and possibly other potential endocrine disruptors, especially in female offspring].
3. Levin ED, Addy N, Baruah A, Elias A, Christopher NC, Seidler FJ, Slotkin TA. Prenatal chlorpyrifos exposure in rats causes persistent behavioural alterations. Neurotoxicol Teratol 2002; 24: 733-741. [This study indicates that late prenatal exposure to chlorpyrifos induces long-term changes in cognitive performance that are distinctly gender-selective].
4. Levin ED, Addy N, Nakajima A, Christopher NC, Seidler FJ, Slotkin TA. 2001. Persistent behavioural consequences of neonatal chlorpyrifos exposure in rats. Dev Brain Res 2001; 130: 83–89. [Sex-selective developmental effects have been seen in animal models exposed to organophosphates. Chlorpyrifos exposure (1 mg/kg/day) in rats during postnatal days 1–4 decreased the number of errors in working and reference memory made by females, but increased the number of such errors made by males. These effects

---

17 Keil AP, Daniels JL, Hertz-Picciotto I. Autism spectrum disorder, flea and tick medication, and adjustments for exposure misclassification: the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study. Environ Health 2014; 13(1): 3
persisted into adolescence and adulthood, indicating a long-term consequence of exposure].


6. Dam K, Seidler FJ, Slotkin TA. Chlorpyrifos exposure during a critical neonatal period elicits gender-selective deficits in the development of coordination skills and locomotor activity. Brain Res Dev Brain Res 2000; 121: 179-187. [Chlorpyrifos given during a critical neonatal period, even at levels below the threshold for overt toxicity, can elicit both immediate and delayed gender-selective behavioural abnormalities].

7. Rauh VA, Perera FP, Horton MK, Whyatt RM, Bansal R, Hao X, Liu J, Barr DB, Peterson BS. Brain anomalies in children exposed prenatally to a common organophosphate pesticide. PNAS 2012; 109: 7871-7876. [Early life chlorpyrifos exposure interferes with normal sexual differentiation of the brain, reducing or reversing the normal sex differences in cognitive and emotion-related behaviours and correlating with sex-specific effects on the neurotransmitter systems that support those behaviours... The high-chlorpyrifos group also displayed disruption of normal sexual dimorphisms in brain structure. These morphological findings are consistent with those from animal models showing that early chlorpyrifos exposure obtunds or reverses normal sex differences in learning, memory, and emotional behaviours].

8. Jedrychowski W, Perera F, Jankowski J, Mrozek-Budzyn D, Mroz E, Flak E, Edwards S, Skarupa A, Lisowska-Miszczyk I. Gender specific differences in neurodevelopmental effects of prenatal exposure to very low-lead levels: The prospective cohort study in three-year olds. Early Hum Dev 2009; 85: 503–510. [This study provides evidence that 3-year old boys are more susceptible than girls to prenatal very low lead exposure. The results of this study should persuade policy makers to consider gender-related susceptibility to lead and possibly to other toxic hazards in setting environmental protection guidelines].

9. Venerosi A, Ricceri L, Tait S, Calamandrei G. Sex dimorphic behaviours as markers of neuroendocrine disruption by environmental chemicals: The case of chlorpyrifos. NeuroToxicology 2012; 33: 1420–1426. [In mice exposed to chlorpyrifos in utero and/or in early development social/emotional responses are differently affected in the two sexes... Chlorpyrifos interferes with maturation of neuroendocrine pathways in rodents and support the hypothesis that in utero or neonatal exposure to low dosages of chlorpyrifos influences the maturation of sex-dimorphic clusters of behavioural items relevant for proper expression of social responses].

**Irreversible binding of neonicotinoids to insect nAChRs**

The DNT Scientific Opinion (2013) states that “the binding of neonicotinoids to insect nAChRs is virtually irreversible” and the BCS report challenges this statement. While the binding is not a covalent one, and therefore can be theoretically reversible, the produced effect is irreversible. However, the available literature supports the PPR comment:

- Imidacloprid is the first highly effective insecticide whose mode of action has been found to derive from almost complete and virtually irreversible blockage of nAChRs in the central nervous system of insects (Abbink, 1991).18
- Neonicotinoids have partially positive charge and can irreversibly bind to nAChRs (Mattiazzi Ušaj et al., 2014).19
- Binding of neonicotinoids to these receptors is irreversible in arthropods (Sánchez-Bayo et al., 2013).20

Besides, Dr. Tennekes has reported that neonicotinoid insecticides cause irreversible and cumulative damage to the central nervous system of insects. The Druckrey-Küpfmüller equation states that if both receptor binding and the effect are irreversible, exposure time would reinforce the hazardous effect (Tennekes 2010a).21 Tennekes (2010b)22 also claims that there is no safe level of exposure, as even tiny amounts of systemic insecticides can have deleterious effects in the long term. This is attributed to the fact that the damage neonicotinoids cause to the central

---

21 Tennekes HA. The significance of the Druckrey-Küpfmüller equation for risk assessment--the toxicity of neonicotinoid insecticides to arthropods is reinforced by exposure time. Toxicology 2010a; 276: 1-4.
22 Tennekes HA. Systemic Insecticides: A disaster in the making. ETS Nederland BV, Zutphen, The Netherlands, 2010b
nervous system of insects is both irreversible and cumulative. Tennekes et al. (2011)\textsuperscript{23} also demonstrated that chemicals that bind irreversibly to specific receptors (including neonicotinoid insecticides) will produce toxic effects in a time-dependent manner, no matter how low the level of exposure. This position has been considered by the Directorate General for internal policies, environment, public health and food safety of the European Parliament.\textsuperscript{24}

**Overall conclusion**

With the data available and the new and limited data presented by the BCS and Exponent, there is insufficient evidence to discard the indications of potential developmental neurotoxicity provided by the regulatory DNT studies performed on imidacloprid and acetamiprid. Accordingly, the recommendation of modifying health-bases reference levels made by the PPR Panel in its DNT Scientific Opinion (2013) continues to be supported by the panel. The PPR Panel notes that until more consistent evidence is provided, uncertainties still persist and hence, human health cannot be guaranteed with the current (unrevised) levels.

The PPR Panel has taken a precautionary approach in its scientific opinion by also considering recent evidence on potential delayed neurological disturbances following prenatal exposure to neurotoxicants. This type of exposure, which may adversely impair the nervous system, has been suggested to be associated with a number of developmental disabilities, such as learning disabilities, attention-deficit hyperactivity disorder, dyslexia, sensory deficits, mental retardation and autism spectrum disorders.\textsuperscript{25}

The current \textit{in vivo} DNT studies may not be sensitive enough to detect subtle effects, such as those on cognition, behaviour or brain morphometry, and might lead to false negatives. Therefore, the scientific assessment of \textit{in vivo} DNT studies should be conservative in their application.


\textsuperscript{25} Giordano G, Costa LG. Developmental Neurotoxicity_Some old and new issues. ISRN Toxicology. Volume 2012, Article ID 814795, 12 pages
Scientific Panel on Plant Protection Products and their Residues

Minutes of the meeting with the Chair of the Working Group on developmental neurotoxicity (DNT) of acetamiprid and imidacloprid

Held on 21 May 2014

(Agreed on 21/05/2014)

Participants

- **Working Group Experts:**
  - Antonio Hernández Jerez

- **EFSA:**
  - Pesticides Unit: Manuela Tiramani

1. Welcome and apologies for absence

The Chair welcomed the participants.

2. Adoption of agenda

The agenda was adopted without changes.

3. Declarations of interest

In accordance with EFSA’s Policy on Independence and Scientific Decision-Making Processes\(^1\) and the Decision of the Executive Director implementing this Policy regarding Declarations of Interests\(^2\), EFSA screened the Annual Declaration of interest and the Specific Declaration of interest) filled in by the expert invited for the present meeting. No conflicts of interests related to the issues discussed in this meeting have been identified during the screening process or at the Oral Declaration of interest at the beginning of this meeting.

---


4. The minutes of the 4th Working Group meeting held on 17-18 Sep 2013 were agreed by written procedure on 2 Oct 2013 and published on the EFSA website 3 Oct 2013.

5. Scientific topic(s) for discussion
   
   5.1 Scientific support to EFSA staff in view of the upcoming meetings with companies for the discussion of the PPR Panel opinion on DNT.

7. Next meeting(s)
   
   To be defined
Scientific Panel on Plant Protection Products and Their Residues

Minutes of the 4th meeting of the Working Group on developmental neurotoxicity (DNT) of acetamiprid and imidacloprid

Held 17-18 09 2013 in Parma

(Agreed on 02 10 2013)

Participants

- **Working Group Experts:**
  - Antonio F. Hernández-Jerez (chair)
  - Karen Ildico Hirsch-Ernst
  - Alberto Mantovani (on 17 Sep)
  - Colin D. Ockleford
  - Anna Price
  - Laura Ricceri

- **Hearing Experts:**
  - None

- **European Commission and/or Member States representatives:**
  - None

- **EFSA:**
  - PRAS Unit: Manuela Tiramani
  - PRAS Unit: Federica Crivellente (on 17 Sep)

1. **Welcome and apologies for absence**
The Chair welcomed the participants.

Apologies were received from Alberto Mantovani for the 18 Sep 2013.
2. Adoption of agenda
The agenda was adopted without changes.

3. Declarations of interest
In accordance with EFSA’s Policy on Independence and Scientific Decision-Making Processes\(^1\) and the Decision of the Executive Director implementing this Policy regarding Declarations of Interests \(^2\), EFSA screened the Annual Declaration of Interest and the Specific Declaration of interest filled in by the experts invited for the present meeting. No conflicts of interests related to the issues discussed in this meeting have been identified during the screening process.

For further details on the outcome of the Oral Declaration of Interests made at the beginning of the meeting, please refer to the Annex I.

4. Agreement of the minutes of the 3\(^{rd}\) Working Group meeting held on 01 07 2013 by TELE-conference
The minutes were agreed on 19 07 2013 and published on the EFSA website on 25 07 2013.

5. Scientific topic(s) for discussion

5.1 Presentation of the draft opinion
The opinion was presented by the rapporteur

5.2 Discussion of the draft opinion
The group discussed the draft opinion in detail.
In particular

- it was agreed to modify the words caudate nucleus/putamen into caudate/putamen because of the specificity of the terminology in experimental rats
- it was agreed to reflect in the text that the huge interspecies differences in LD50s could indicate the need of using human cells culture for in vitro testing
- the concept of efficacy introduced in addition to “affinity” of receptors should be defined in the text (e.g. in the glossary)
- the paragraph “Physiological role of nAChRs during brain development” was rearranged to improve clarity
- some new references were included in the text to improve readability and clarity
- it was noted that in the article by Mohamed et al, 2009 there is a gap between ingestion and sampling time in patients likely poisoned with imidacloprid, which were likely treated with atropine because of suspected OP poisoning, possibly enhancing the effects of IMI administration. It was agreed to reflect this in the text

some paragraphs will need further check before final version will be circulated for comments
the possibility and the need of deriving new reference values based on the analysis of the toxicological data

5.3 Next steps
The rapporteur will further work on the updated version prior to circulate for the final commenting

6. Any Other Business:
None

7. Next meeting(s)
None
Annex I

Interests and actions resulting from the oral declarations of interests done at the beginning of the meeting

a) With regard to this meeting Dr. Karen Ildico Hirsch-Ernst declared the following interest: BfR has been involved in the assessment of imidacloprid within the context of Germany serving as RMS. In accordance with EFSA’s Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director implementing this Policy regarding Declarations of Interests, and taking into account the specific matters discussed at the meeting in question, the interest above was not deemed to represent a conflict of Interest for the expert concerned.
Scientific Panel on Plant Protection Products and Their Residues
Minutes of the 3rd meeting of the Working Group on developmental neurotoxicity (DNT) of acetamiprid and imidacloprid
Tele-conference, 01 07 2013
(Agreed on 19 07 2013)

Participants

- **Working Group Experts:**
  - Antonio F. Hernández-Jerez (chair)
  - Karen Ildico Hirsch-Ernst
  - Alberto Mantovani
  - Colin D. Ockleford
  - Anna Price
  - Laura Ricceri

- **Hearing Experts:**
  - None

- **European Commission and/or Member States representatives:**
  - None

- **EFSA:**
  - PRAS Unit: Manuela Tiramani
  - PRAS Unit: Federica Crivellente

1. Welcome and apologies for absence
The Chair welcomed the participants.
No apologies were received.
2. Adoption of agenda
The agenda was adopted without changes.

3. Declarations of interest
In accordance with EFSA’s Policy on Independence and Scientific Decision-Making Processes\(^1\) and the Decision of the Executive Director implementing this Policy regarding Declarations of Interests\(^2\), EFSA screened the Annual Declaration of Interest and the Specific Declaration of interest filled in by the experts invited for the present meeting. No conflicts of interests related to the issues discussed in this meeting have been identified during the screening process.

For further details on the outcome of the Oral Declaration of Interests made at the beginning of the meeting, please refer to the Annex I.

4. Agreement of the minutes of the 2\(^{nd}\) Working Group meeting held on 18-19 04 2013, Parma.
The minutes were agreed by written procedure on 26 04 2013 and published on the EFSA website on 07 05 2013.

5. Scientific topic(s) for discussion

5.1 Presentation of the draft opinion (EFSA-Q-2012-00958)
The opinion was presented by the rapporteur

5.2 Discussion of the draft opinion
The group discussed the draft opinion in detail.
In particular it was agreed to:

- Move human data from the literature to chapter 3 (under the “dose-response relationship” section)
- Move all the toxicological data of ACE and IMI in chapter 5
- To include a paragraph on cerebellar granule cells cultures without KCl medium
- To move the section on blood brain barrier in chapter 1 under the ADME section
- To add a subsection with the comments of the PPR Panel on the results of the US EPA studies on ACE and IMI
- To add a short introduction at the beginning of the chapter “Conclusions and recommendations”

5.3 Next steps
The deadlines and the tasks for progressing in the work were allocated

6. Any Other Business
   None

7. Next meeting(s)
   Physical meeting in Parma (17-18 September)
Annex I

Interests and actions resulting from the oral declarations of interests done at the beginning of the meeting

a) With regard to this meeting Dr. Karen Ildico Hirsch-Ernst declared the following interest: BfR has been involved in the assessment of imidacloprid within the context of Germany serving as RMS. In accordance with EFSA’s Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director implementing this Policy regarding Declarations of Interests, and taking into account the specific matters discussed at the meeting in question, the interest above was not deemed to represent a conflict of Interest for the expert concerned.
Participants

- **Working Group Experts:**
  - Antonio F. Hernández-Jerez (chair)
  - Karen Ildico Hirsch-Ernst
  - Alberto Mantovani
  - Colin D. Ockleford
  - Anna Price
  - Laura Ricceri

- **Hearing Experts:**
  - None

- **European Commission and/or Member States representatives:**
  - None

- **EFSA:**
  - PRAS Unit: Manuela Tiramani

1. **Welcome and apologies for absence**

   The Chair welcomed the participants.

   No apologies were received.
2. Adoption of agenda
The agenda was adopted without changes.

3. Declarations of interest
In accordance with EFSA’s Policy on Independence and Scientific Decision-Making Processes\(^1\) and the Decision of the Executive Director implementing this Policy regarding Declarations of Interests\(^2\), EFSA screened the Annual Declaration of Interest and the Specific Declaration of interest filled in by the experts invited for the present meeting. No conflicts of interests related to the issues discussed in this meeting have been identified during the screening process.

For further details on the outcome of the Oral Declaration of Interests made at the beginning of the meeting, please refer to the Annex I.

4. **Scientific topic(s) for discussion**

   **4.1 Discussion of the Bayer report (position paper)**
   The report was discussed, with particular focus on the information regarding the correlation between “in vivo” application of single doses of imidacloprid and the respective plasma concentrations.

   **4.2 Presentation of the draft opinion (EFSA-Q-2012-00958)**
   The opinion was presented by the rapporteur

   **4.3 Discussion of the draft opinion**
   The group discussed the draft opinion in detail.
   In particular it was agreed to
   - add a chapter for the general physicochemical properties of acetamiprid and imidacloprid
   - expand the part of the opinion related to the physiology of nAChRs
   - amend some formal aspects
   - reorganise the structure reallocating the position of certain paragraph/chapters

   **4.4 Next steps**
   The deadlines and the tasks for progressing in the work were allocated

5. **Any Other Business:** none

6. **Next meeting(s)**
   Teleconference (1\textsuperscript{st} July 2013 tentative date)
Annex I

Interests and actions resulting from the oral declarations of interests done at the beginning of the meeting

a) With regard to this meeting Dr. Karen Ildico Hirsch-Ernst declared the following interest: BfR has been involved in the assessment of imidacloprid within the context of Germany serving as RMS. In accordance with EFSA’s Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director implementing this Policy regarding Declarations of Interests, and taking into account the specific matters discussed at the meeting in question, the interest above was not deemed to represent a conflict of Interest for the expert concerned.
SCIENTIFIC PANEL ON PLANT PROTECTION PRODUCTS AND THEIR RESIDUES

Minutes of the 1st meeting of the Working Group on developmental neurotoxicity (DNT) of acetamiprid and imidacloprid
Held on 11-12 February 2013, Parma

(Agreed on 22 February 2013)

Participants

- **Working Group Experts:**
  - Antonio F. Hernández-Jerez (chair)
  - Karen Ildico Hirsch-Ernst
  - Colin D. Ockleford
  - Anna Price
  - Laura Ricceri

- **Hearing Experts:**
  - None

- **European Commission and/or Member States representatives:**
  - None

- **EFSA:**
  - PRAS Unit: Manuela Tiramani

1. Welcome and apologies for absence
The Chair welcomed the participants.
Apologies were received from Alberto Mantovani.
2. Adoption of agenda

The agenda was adopted without changes.

3. Declarations of interest

In accordance with EFSA’s Policy on Independence and Scientific Decision-Making Processes[^3] and the Decision of the Executive Director implementing this Policy regarding Declarations of Interests[^4], EFSA screened the Annual Declaration of Interest and the Specific Declaration of interest filled in by the experts invited for the present meeting. No conflicts of interests related to the issues discussed in this meeting have been identified during the screening process.

For further details on the outcome of the Oral Declaration of Interests made at the beginning of the meeting, please refer to the Annex I.

4. Scientific topic(s) for discussion

4.1 The mandate
The mandate received from COM with the questions the opinion will have to address was presented (question number in RoQ)

4.2 Paper by Kimura-Kuroda et al 2012 “Nicotine-Like Effects of the Neonicotinoid Insecticides Acetamiprid and Imidacloprid on Cerebellar Neurons from Neonatal Rats”
The group discussed the paper in detail, with regard to the scope, methodology applied and results.

4.3 Analysis of the relevant OECD guidelines in the field of developmental toxicity
The OECD guideline for developmental neurotoxicity testing (n. 426) was discussed in length by the WG.

4.4 Discussion on the toxicological assessment of acetamiprid and imidacloprid as in the Draft Assessment Reports considered in the peer review process at EU level, with particular focus on the DNT
The toxicological assessments currently available in EU and outside EU were considered and discussed, with particular reference to the DNT effects.
Overall, according to the EU studies for both acetamiprid and imidacloprid, DNT potential was not considered a concern (as for imidacloprid a specific DNT study is available, whereas it has not been done for acetamiprid).

With regard to the reference values, they have the same order of magnitude for both a.s.
According to the US EPA studies, none of the 2 a.s. is representing a public health concern in terms of developmental neurotoxicity (for both a.s. specific tests are available)

4.5 Layout of the opinion and allocation of tasks
The lay out was discussed and tasks allocated.

5. Any Other Business: none

6. Next meeting(s)
   18-19 April 2013, EFSA – Parma
Annex I

Interests and actions resulting from the oral declarations of interests done at the beginning of the meeting

With regard to this meeting Dr. Karen Ildico Hirsch-Ernst declared the following interest: BfR has been involved in the assessment of imidacloprid within the context of Germany serving as RMS. In accordance with EFSA’s Policy on Independence and Scientific Decision-Making Processes and the Decision of the Executive Director implementing this Policy regarding Declarations of Interests, and taking into account the specific matters discussed at the meeting in question, the interest above was not deemed to represent a conflict of Interest for the expert concerned.